| Literature DB >> 24235910 |
Yasir Arafat1, Saqib Ali, Saira Shahzadi, Muhammad Shahid.
Abstract
Heterobimetallic complexes of Zn(II) and Sn(IV) with sarcosine have been synthesized at room temperature under stirring conditions by the reaction of sarcosine and zinc acetate in 2 : 1 molar ratio followed by the stepwise addition of CS2 and organotin(IV) halides, where R = Me, n-Bu, and Ph. The complexes were characterized by elemental analysis, FT-IR and NMR ((1)H, (13)C) spectroscopy. IR data showed that the ligand acts in a bidentate manner. NMR data revealed the four coordinate geometry in solution state. In vitro antimicrobial activities data showed that complexes (3) and (4) were effective against bacterial and fungal strains with few exceptions.Entities:
Year: 2013 PMID: 24235910 PMCID: PMC3819876 DOI: 10.1155/2013/351262
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Figure 1Chemical structure of sarcosine.
Scheme 1Physical data of heterobimetallic complexes with sarcosine.
| Comp. | Molecular formula | Mol. weight | % yield | m.p (°C) | Elemental analysis | |||
|---|---|---|---|---|---|---|---|---|
| % C | % H | % N | % S | |||||
| HL | C3H7O2N | 89.09 | — | 208 | 40.45 | 7.92 | 15.71 | — |
| (40.42) | (7.95) | (15.68) | ||||||
| ( | C12H22O4N2S4Cl2ZnSn2 | 760.31 | 75 | 121-122 | 18.95 | 2.91 | 3.68 | 16.87 |
| (18.99) | (2.95) | (3.64) | (16.89) | |||||
| ( | C24H46O4N2S4Cl2ZnSn2 | 928.63 | 68 | 87–91 | 31.04 | 4.99 | 3.01 | 13.81 |
| (31.07) | (4.96) | (3.04) | (13.78) | |||||
| ( | C32H30O4N2S4Cl2ZnSn2 | 1008.53 | 57 | 107–109 | 38.10 | 2.99 | 2.77 | 12.71 |
| (39.12) | (2.96) | (2.74) | (12.74) | |||||
| ( | C14H28O4N2S4ZnSn2 | 719.61 | 67 | 145-146 | 23.36 | 3.92 | 3.89 | 17.82 |
| (23.39) | (3.96) | (3.92) | (17.78) | |||||
| ( | C32H64O4N2S4ZnSn2 | 971.53 | 51 | 224-225 | 39.55 | 6.64 | 2.88 | 13.20 |
| (39.50) | (6.68) | (2.85) | (13.17) | |||||
| ( | C44H40O4N2S4ZnSn2 | 1091.89 | 73 | 86–88 | 48.39 | 3.69 | 2.56 | 11.74 |
| (48.36) | (3.65) | (2.59) | (11.78) | |||||
IR spectral data (cm−1) of heterobimetallic complexes with sarcosine.
| Comp no. |
|
| Δ |
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| |||||||||
| HL | 3365 | 1621 | 1407 | 214 | — | — | — | — | — | — |
| ( | — | 1642 | 1462 | 180 | 1033 | 955 | 526 | 461 | 311 | 364 |
| ( | — | 1618 | 1433 | 185 | 1013 | 942 | 530 | 472 | 302 | 352 |
| ( | — | 1602 | 1440 | 162 | 1025 | 988 | 272 | 466 | 318 | 347 |
| ( | — | 1622 | 1456 | 166 | 1023 | 938 | 538 | 485 | — | 371 |
| ( | — | 1635 | 1468 | 167 | 1043 | 965 | 547 | 456 | — | 385 |
| ( | — | 1650 | 1470 | 180 | 1030 | 970 | 280 | 480 | — | 310 |
1H NMR dataa–d (ppm) of heterobimetallic complexes with sarcosine.
| Proton no. | HL | ( | ( | ( | ( | ( | ( |
|---|---|---|---|---|---|---|---|
| 2, 2′ | 3.15s | 3.97s | 3.99s | 3.88s | 3.74s | 3.63s | 3.95s |
| 3, 3′ | 2.48s | 2.89s | 2.80s | 2.96s | 2.85s | 2.94s | 2.79s |
aCompound (1) Sn-CH3Cl, 1.27s 2 J[96]; compound (2) Sn-CH2CH2CH2CH3Cl, 0.88–0.93m, 0.23t (7.2); compound (3) Sn-C6H5Cl, 7.91d 2 J[82], 7.50–7.53m, 7.42–7.50m; compound (4) Sn-CH3, 0.51s 2 J[82]; compound (5) Sn-CH2CH2CH2CH3, 0.64–1.1m, 0.23t (7.2); compound (6) Sn-C6H5, 7.91d 2 J[82], 7.50–7.53m, 7.42–7.50m.
bMultiplicity is given as s: singlet, d: doublet, t: triplet, m: multiplet.
cCoupling constant, J[119Sn, 1H] and J[1H, 1H] in Hz are given in square bracket and parenthesis, respectively.
d
13C NMR dataa,b (ppm) of heterobimetallic Zn(II) and Sn(IV) complexes with sarcosine.
| Carbon | HL | ( | ( | ( | ( | ( | ( |
|---|---|---|---|---|---|---|---|
| 1, 1′ | 179.2 | 186.3 | 181.9 | 183.7 | 185.4 | 184.3 | 183.8 |
| 2, 2′ | 56.6 | 56.8 | 56.3 | 56.9 | 56.7 | 56.6 | 56.8 |
| 3, 3′ | 41.5 | 41.3 | 41.3 | 41.5 | 41.4 | 41.2 | 41.5 |
| –CSS | — | 202.6 | 202.5 | 202.8 | 201.7 | 202.8 | 202.7 |
aCompound (1) Sn-CH3Cl, (C-α) 2.1 1 J[397]; compound (2) Sn-CH2CH2CH2CH3Cl, (C-α) 29.5, (C-β) 27.4, (C-γ) 26.2, (C-δ) 13.9; compound (3) Sn-C6H5Cl, (C-α) 137.6 1 J[640], (C-β) 132.8 2 J[49.0], (C-γ) 129.9, (C-δ) 124.8; compound (4) Sn-CH3, (C-α) 2.3 1 J[396]; compound (5) Sn-CH2CH2CH2CH3, (C-α) 31.1 [349], (C-β) 27.1 2 J[21], (C-γ) 28.2 3 J[63], (C-δ) 14.1; compound (6) Sn-C6H5, (C-α) 138.0 1 J[640], (C-β) 133.0 2 J[49.0], (C-γ) 130.0, (C-δ) 125.1.
bChemical shifts (δ) in ppm: J[119Sn, 13C] in Hz is listed in parenthesis.
Antibacterial activity dataa–e of complexes and ligand against selected bacterial strains.
| Compound no. | Bacterial inhibition zone (mm) | |||
|---|---|---|---|---|
|
|
|
|
| |
| HL | 12.5c ± 0.86 | 13.0c ± 1.00 | 12.5c ± 0.86 | 12.0c ± 1.41 |
| ( | 20.8bc ± 1.00 | 18.0c ± 1.00 | 25.2c ± 0.86 | 21.0ab ± 1.00 |
| ( | 21.0bc ± 1.00 | 20.5bc ± 0.86 | 27.5bc ± 0.86 | 24.5ab ± 0.86 |
| ( | 20.8bc ± 1.00 | 18.6c ± 1.00 | 26.2c ± 0.86 | 21.3ab ± 1.00 |
| ( | 30.0ab ± 1.41 | 21.5bc ± 1.65 | 28.0bc ± 1.41 | 23.0ab ± 1.00 |
| ( | 32.5ab ± 1.65 | 54.5a ± 0.86 | 51.0a ± 1.00 | 32.5a ± 1.65 |
| ( | 31.5ab ± 0.86 | 33.0bc ± 1.41 | 32.0ab ± 1.00 | 30.0ab ± 1.41 |
| Ampicillin | 38.5a ± 0.86 | 40.0ab ± 1.41 | 39.5ab ± 0.86 | 32.0ab ± 1.41 |
aConcentration: 1 mg/mL in DMSO.
bStandard: ampicillin.
c0: no activity, 5–10: activity present, 11–25: moderate activity, 26–40: strong activity.
dAntibacterial values are mean ± S.D of samples analyzed individually in triplicate at P < 0.1.
eDifferent letters in superscript indicate significant differences.
Antifungal activity dataa–e of complexes and ligand against selected fungal strains.
| Compound no. | Fungal inhibition zone (mm) | |||
|---|---|---|---|---|
|
|
|
|
| |
| HL | 27.0ab ± 1.00 | 11.5c ± 0.86 | 37.5ab ± 0.86 | 14.5bc ± 1.65 |
| ( | 26.4ab ± 1.00 | 19.3bc ± 1.00 | 20.2bc ± 1.65 | 20.3ab ± 0.86 |
| ( | 20.0c ± 1.41 | 19.0bc ± 1.00 | 20.5bc ± 1.65 | 20.5bc ± 0.86 |
| ( | 26.9bc ± 1.41 | 20.2ab ± 1.65 | 35.2bc ± 1.65 | 21.2bc ± 0.86 |
| ( | 30.0ab ± 1.41 | 18.5bc ± 0.86 | 19.5c ± 1.65 | 18.5bc ± 0.86 |
| ( | 30.0ab ± 1.41 | 39.5ab ± 1.65 | 37.0ab ± 1.65 | 33.5 a ± 1.65 |
| ( | 28.5ab ± 0.86 | 25.0bc ± 1.00 | 32.0bc ± 1.41 | 19.5bc ± 0.86 |
| Fluconazole | 30.5a ± 0.86 | 41.5a ± 0.86 | 54.0a ± 1.41 | 12.5c ± 0.86 |
aConcentration: 1 mg/mL in DMSO.
bStandard: fluconazole.
c0: no activity, 5–10: activity present, 11–25: moderate activity, 26–40: strong activity.
dAntibacterial values are mean ± S.D of samples analyzed individually in triplicate at P < 0.1.
eDifferent letters in superscript indicate significant differences.